ClinicalTrials.gg
CompletedNCT01628094Updated Nov 2, 2016

ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

A Phase 2 interventional study of RO5024048 and RO5190591 in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 31 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing danoprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. danoprevir · Hepatitis C, Chronic.

Enrollment
4th of 10
110 · median 79
Started
2012
with 1 other
Phase 2
7 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
7 of 10
Hoffmann-La Roche

Among the 10 studies testing danoprevir in Hepatitis C, Chronic, this one is the 4th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 2, and was the 6th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 10 studies testing danoprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About danoprevir

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing danoprevir in Hepatitis C, Chronic as a file.
02

Study summary

This randomized, open-label, multicenter study will evaluate the safety , efficacy and tolerability of the combination treatment RO5466731, RO5190591, ritonavir and Copegus (ribavirin) with or without RO5024048 in patients with chronic hepatitis C genotype 1. In Part 1, treatment-naïve patients will be randomized to receive treatment with RO5466731, RO5190591 plus ritonavir, and Copegus, with or without RO5024048. In Part 2, further treatment-naïve patients will receive a successful regimen from Part 1, or a reduced intensity regimen, and patients who have previously experienced null response to interferon-based treatment will be added to the study.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Chronic genotype 1 of >/= 6 months duration at screening
  • Part 1 and Part 2: Naïve to treatment with interferon (pegylated or non-pegylated). Patients who have participated in studies investigating a direct-acting antiviral agent with or without interferon are excluded
  • Part 2: Treatment experienced patients having a previous null response to treatment with interferon containing regimen
  • Liver or non-invasive (e.g. Fibroscan) evaluation in the past 24 calendar months showing absence of cirrhosis or incomplete/transition to cirrhosis
  • (BMI) 18 to 35 kg/m2 inclusive and body weight >/= 45 kg

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women or males with female partners who are pregnant or lactating
  • Decompensated liver disease or impaired liver function (as defined by protocol)
  • Cirrhosis or incomplete/transition to cirrhosis
  • Non- chronic liver disease
  • Positive for or infection
  • History of pre-existing renal disease
  • History of severe cardiac disease
  • History of neoplastic disease within the last 5 years, except for localized or in situ carcinoma of the skin
  • History of drug abuse within the last year; history of cannabinoid use is not excluded
  • Evidence of alcohol abuse within 1 year of screening and consumption of more than 2 units of alcohol per day
  • Medical condition that requires use of systemic
  • Received warfarin or other anticoagulants during the 21 days immediately prior to screening or is expected to require warfarin or other anticoagulants during the study
  • Anticipated use or need for significant medical treatment during the study or use of concomitant medications or nutrients that are excluded by protocol (e.g. drugs that are with ritonavir, hormonal methods of )
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    A: GT1a 3DAA

    including RO5466731, RO5190591, ritonavir, ribavirin \[Copegus\] and RO5024048

    Drug: RO5024048 · Drug: RO5190591 · Drug: RO5466731 · Drug: ribavirin [Copegus] · Drug: ritonavir

  • Experimental
    B: GT1a 3DAA

    including RO5466731, RO5190591, ritonavir, ribavirin \[Copegus\] and RO5024048

    Drug: RO5024048 · Drug: RO5190591 · Drug: RO5466731 · Drug: ribavirin [Copegus] · Drug: ritonavir

  • Experimental
    C: GT1a 2DAA

    including RO5466731, RO5190591, ritonavir and ribavirin \[Copegus\]

    Drug: RO5190591 · Drug: RO5466731 · Drug: ribavirin [Copegus] · Drug: ritonavir

  • Experimental
    D: GT1b 3DAA

    including RO5466731, RO5190591, ritonavir, ribavirin \[Copegus\] and RO5024048

    Drug: RO5024048 · Drug: RO5190591 · Drug: RO5466731 · Drug: ribavirin [Copegus] · Drug: ritonavir

  • Experimental
    E: GT1b 2DAA

    including RO54664731, RO5190591, ritonavir and ribavirin \[Copegus\]

    Drug: RO5190591 · Drug: RO5466731 · Drug: ribavirin [Copegus] · Drug: ritonavir

  • Experimental
    Part II

    Drug: RO5024048 · Drug: RO5190591 · Drug: RO5466731 · Drug: ribavirin [Copegus] · Drug: ritonavir

06

What researchers measure

Primary outcomes

  1. Sustained virological response (defined as undetectable serum HCV RNA) 12 weeks after end of treatment

    Time frame: approximately 20 months

  2. Safety: Incidence of adverse events

    Time frame: approximately 20 months

Secondary outcomes

  1. Antiviral activity: Change in serum HCV RNA levels

    Time frame: from baseline to 24 weeks after end of treatment

  2. Pharmacokinetics in coadministration: Area under the concentration-time curve (AUC)

    Time frame: Pre-dose Weeks 1, 2, 3, 4, 6, 10, and 12 and up to 12 hours post-dose Weeks 1, and 4 or 3 and 6

  3. HCV drug resistance

    Time frame: approximately 20 months

  4. Quality of life: Short-Form 36v2/Brief Fatigue Inventory questionnaires

    Time frame: approximately 20 months

07

Study locations

31 sites
  • LaJolla, California 92037, United States
  • Englewood, Colorado 80113, United States
  • South Miami, Florida 33143, United States
  • Marietta, Georgia 30060, United States
  • Honolulu, Hawaii 96813, United States
  • Chicago, Illinois 60637, United States
  • Kansas City, Kansas 66160, United States
  • Detroit, Michigan 48202, United States
  • Saint Louise, Missouri 63104, United States
  • Asheville, North Carolina 28801, United States
  • Dallas, Texas 75246, United States
  • Houston, Texas 77030, United States
  • San Antonio, Texas 78215, United States
  • San Antonio, Texas 78234, United States
  • Vancouver, Washington 98664, United States
  • Kingswood, New South Wales, Australia
  • Sydney, New South Wales 2050, Australia
  • Westmead, New South Wales 2145, Australia
  • Herston, Queensland 4029, Australia
  • Parkville, Victoria 3052, Australia
  • Berlin, 13353, Germany
  • Frankfurt Am Main, 60590, Germany
  • Hamburg, 20099, Germany
  • Hannover, 30625, Germany
  • Dunedin, 9016, New Zealand
  • Grafton, 1010, New Zealand
  • Hamilton, New Zealand
  • Bialystok, 15-540, Poland
  • Chorzow, 41-500, Poland
  • Lodz, 91-357, Poland
  • Myslowice, 41-400, Poland
08

References and documents

Publications

  • Jensen DM, Brunda M, Elston R, Gane EJ, George J, Glavini K, Hammond JM, Le Pogam S, Najera I, Passe S, Piekarska A, Rodriguez I, Zeuzem S, Chu T; ANNAPURNA study investigators. Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver Int. 2016 Apr;36(4):505-14. doi: 10.1111/liv.12997. Epub 2015 Dec 12. PubMed 26519669 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2012
First posted
Jun 26, 2012
Start
Jun 2012
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results delay requested
Jun 30, 2016
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01628094
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 26, 2012
Start date
Jun 2012
Primary completion
Nov 2013
Completion
Nov 2013
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Danoprevir · Setrobuvir · Ritonavir

Start the discussion